成人小说亚洲一区二区三区,亚洲国产精品一区二区三区,国产精品成人精品久久久,久久综合一区二区三区,精品无码av一区二区,国产一级a毛一级a看免费视频,欧洲uv免费在线区一二区,亚洲国产欧美中日韩成人综合视频,国产熟女一区二区三区五月婷小说,亚洲一区波多野结衣在线

立即打開
The right dose of pharma stocks

The right dose of pharma stocks

2009年06月25日

????Paul Abel of Kinetics Medical Fund calls for a simple balance that doesn't waste time looking for the next big superstar.

????By Alyssa Abkowitz

????Fund manager Paul Abel has one warning for investors looking to delve into pharmaceutical and biotech stocks: Don't think you'll spot the next Amgen.

????Abel, who manages the Kinetics Medical Fund, is a true believer of start-up companies, but he advises investors to think of them more as "publicly traded venture capital" rather than the next big biotech superstar. "When you've adopted that sort of mindset," he says, "you can pick them judiciously."

????Abel's strategy for investing in biotech and pharmaceutical stocks is simple: One-third of his portfolio consists of Big Pharma, one-third is what he calls "profitable biotechs," and the final third is the previously mentioned publicly traded venture capital, or yet-to-be profitable biotechs.

????The Kinetics Medical Fund has fallen about 10% over the last year, according to Morningstar. But it's up 9% year-to-date, while its overall health category is up less than half a percent. It has 46 holdings and assets of about $18 million.

????Abel says part of the attraction of large pharmaceuticals and some biotechs these days is their lack of exposure to the credit markets. Many Big Pharma companies sit on large amounts of cash and can borrow money easily. He points to the $30 billion bridge loan Pfizer (PFE, Fortune 500) secured at the end of January to finance its $64 billion acquisition of Wyeth.

????While pharmas and biotechs aren't immune from the current credit crunch, Abel says the damage has been collateral. "Over the past couple of months we've experienced a strange systemic arbitrage," he says. "But you can't sell a dollar for twenty-five cents for very long."

????One of the biggest issues for Abel in picking stocks for his fund is keeping companies that fit into the middle third of his portfolio -- the profitable biotechs. "For about five years now we've lost roughly one company per quarter out of our portfolio through an acquisition," Abel says. "It's been lucrative but a little unnerving at the same time."

????Another hot topic that's weighing on Abel is the health care reform debate. Assuming Congress could pass some sort of universal measure, there may be some pricing pressure on pharmaceutical companies, but he thinks it would be offset by market opportunity because a slew of people who didn't have access to drugs would be able to fill their prescriptions.

????In deciding which companies to invest in, Abel follows a bottom-up mentality. He first evaluates the company's underlying business model and how it makes its money. Then he sees if he can buy it at a discount to the actual value of the company. Here are some of his top picks:

????In Big Pharma: (NVS) The company, which Abel has held for awhile, just unveiled its first batch of swine flu vaccines ahead of schedule and its CEO predicted 2009 will be its best year ever. In this category, value investing is the way to go, Abel says, particularly because of the dividend yields of 4% to 6% that many Big Pharmas such as Novartis offer.

????In profitable biotechs: Biogen Idec (BIIB) Abel liked Biogen even before Carl Iachn eyed the nimble company. "They've been able to execute the business model repeatedly by introducing drugs and growing their revenue," he says. The fourth quarter of 2008 was Biogen's first billion-dollar quarter and it's projecting $5 billion for this year.

????In the smaller space: Affymetrix (AFFX) Only a couple months ago, the company was trading around $2 a share -- a major discount to Affymetrix's book value -- or really its cash position because its operations were financed through the sale of equity. "When the company was trading at thirty cents on the dollar to its cash position it almost became too easy," Abel says. With smaller companies, Abel recommends buying a small position and then adding to it if you like what you see.

????"Some pundits say that's not a viable strategy anymore," Abel says of the power of buy and hold. "But I disagree. There's no need to sell the winners."

掃碼打開財富Plus App
久久国产AVJUST麻豆av天堂电影网| 亚洲精品国产偷五月天丁香| 国产欧美日韩在线一区二区不卡| 亚洲亚洲人成综合网站| 久久久久精品免费视频不卡| 久久久久久久国产精品影视| 99久久精品免费热37| 亚洲欧美精品综合在线观看| 久久人妻av一区二区软件| 国产精品无码无卡毛片不卡视| 亚洲欧洲精品天堂一级无码| 好男人高清免费观看日本| 亚洲AⅤ综合在线欧美一区| 亚洲人成网址在线播放狼友| 免费一级全黄少妇性色生活片| 无码中文人妻在线一区二区三区| 天天躁狠狠躁狠狠躁性色av| 黄色无码视频在线观看| 亚洲熟妇自偷自拍另欧美| 成人区人妻精品一区二区不卡| 99在线精品视频在线观看 | 学生妹一级J人片内射视频| 日韩中文字幕无码不卡| 久久久久久亚洲精品人妻少妇| 日本精品熟妇免费一区二区三区| 天天摸天天做天天爽2020| 亚洲欧美日韩中文字幕在线国产成人高清亚洲亚洲日本人成网站| 99热门精品一区二区三区无码| 国产乱妇乱子在线播视频播放网站| 欧美亚洲综合另类精品国产色拍| 国产日产韩产一区二区精品无码| 国产精品视频全国免费观看| 蜜臀精品视频在线观看| 亚洲中文久久精品无码浏不卡| 日韩精品视频美在线精品视频| 桃花视频www欧美日韩内射| 一区二区免费国产区二区| 久久精品国产亚洲精品| 亚洲精品人成无码中文毛片| 国产午夜无码精品免费看| 亚洲中文无码亚洲人网站|